DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2238077/novo-nordisk-nvo-up-on-upbeat-data-from-new-obesity-pill-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2238077 Mar 08, 2024 - Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day. 0

https://www.zacks.com/stock/news/2239193/novo-nordisk-nvo-is-considered-a-good-investment-by-brokers-is-that-true?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2239193 Mar 12, 2024 - Based on the average brokerage recommendation (ABR), Novo Nordisk (NVO) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying? 0

https://www.zacks.com/stock/news/2239424/all-you-need-to-know-about-novo-nordisk-nvo-rating-upgrade-to-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2239424 Mar 12, 2024 - Novo Nordisk (NVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. 0

https://www.zacks.com/stock/news/2240060/the-zacks-analyst-blog-highlights-novo-nordisk-tesla-airbnb-oneok-and-cdw?cid=CS-ZC-FT-press_releases-2240060 Mar 13, 2024 - Novo Nordisk, Tesla, Airbnb, ONEOK and CDW are part of the Zacks top Analyst Blog. 0

https://www.zacks.com/stock/news/2241296/pharma-stock-roundup-azn-s-new-acquisition-fda-updates-for-nvo-lly-and-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2241296 Mar 15, 2024 - AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks. 0

https://www.zacks.com/stock/news/2245039/novo-nordisk-nvo-gets-positive-chmp-opinion-for-insulin-icodec?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245039 Mar 22, 2024 - Novo Nordisk (NVO) receives a positive opinion from the CHMP for once-weekly basal insulin icodec for the treatment of diabetes in adults. 0

https://www.zacks.com/stock/news/2247400/pharma-stock-roundup-abbv-nvo-s-new-m-as-fda-nod-to-jnj-mrk-pah-drugs?cid=CS-ZC-FT-analyst_blog|stock_roundup-2247400 Mar 28, 2024 - While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs. 0

https://www.zacks.com/stock/news/2247877/why-novo-nordisk-nvo-is-a-top-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_focus_list-2247877 Mar 29, 2024 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List. 0

https://www.zacks.com/stock/news/2249062/wall-street-analysts-think-novo-nordisk-nvo-is-a-good-investment-is-it?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2249062 Apr 02, 2024 - The average brokerage recommendation (ABR) for Novo Nordisk (NVO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock? 0

https://www.zacks.com/stock/news/2252191/healthcare-etfs-for-the-weight-loss-drug-boom-beyond?cid=CS-ZC-FT-etf_spotlight-2252191 Apr 08, 2024 - We discuss attractive investment opportunities within the healthcare industry. 0